MelanomaArchives
A prognostic model for uveal melanoma in Asian populations: a comparative analysis of clinical features and gene expression patterns using the TRACE and TCGA data
Melanoma 5 min.
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults [1]. Despite advances in primary tumor treatment, survival rates have not improved, largely due to early subclinical micrometastasis at early stages [2]. Recently, Tebentafusp became the first drug showing a survival benefit...
Research hotspots and trends of immunotherapy and melanoma: A bibliometric analysis during 2014–2024
Melanoma 1 min.
Over the last decade, the increasing global prevalence of melanoma has sparked growing interest in immunotherapies, which show significant potential against this form of skin cancer. This research aims to offer a framework to guide future studies and inspire new research directions. In this study, we...
A Novel Imidazoquinoline With TLR 7/8, STING, and Inflammasome Activity Demonstrates Antitumor Efficacy in Mouse Melanoma and Neu-Driven Mammary Adenocarcinoma.
Melanoma 1 min.
Activation of endosomal Toll-like receptors 7 and 8 in antigen-presenting cells typically results in the induction of type I interferons (IFN). We previously reported a series of imidazoquinolines that potently activate TLR7/8. The potency and selectivity of these compounds can be tuned via substitutions...
Modeling anti-tumor immune responses using patient-derived melanoma organoids
Melanoma 6 min.
Melanoma, a highly aggressive form of skin cancer, poses significant challenges in treatment, especially in its metastatic stage. However, during the last decade, treatment with clinical introduction of immunomodulatory therapies has dramatically changed the outcome of melanoma patients with advanced...
A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model
Melanoma 5 min.
Over the past decade, immune checkpoint inhibitors (ICIs), such as anti–programmed cell death protein 1 (PD-1) and anti–programmed death-ligand 1 (PD-L1) antibodies, have been used to treat various types of cancers and have significantly improved patient prognosis. However, ICI monotherapy...
